Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In Study 2, 271 treatment-emergent AEs were reported in 28 of 31 subjects
Patients switching medications should be monitored for these potential adverse effects, and their dose escalation plan should be tailored accordingly with the help of a licensed professional
This page presents its documented protocol as research-use-only reference information, not a prescription
25 GLP-1 GIP
Short-acting agents like exenatide immediate-release (Byetta) and lixisenatide (Adlyxin) do not carry this warning
US$ 25.57
US$ 27.12
US$ 28.09
US$ 28.82
US$ 23.63
US$ 24.37
US$ 21.55
US$ 23.84
